in vitro News and Research

RSS

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

Rheonix receives U.S patent for microfluidic device

Rheonix, Inc., developer of the Rheonix CARD system to provide multiplexed endpoint analysis for a wide breadth of diagnostic applications, announced that on November 16, 2010 the U.S. Patent and Trademark Office issued Patent Number 7,832,429 "Microfluidic Pump and Valve Structures and Fabrication Method" to the Company.

18 Nov 2010

Imec and PEIRA develop platform for in-vitro study of brain tissue

The nanoelectronics research centre imec and Peira, a Belgium-based manufacturer of pharmaceutical and chemical research instruments, jointly developed an innovative slice-tilting instrument for in-vitro research on brain tissue. The new tool enables long-term studying of brain cultures through electronic stimulation and read-out, essential in getting insight into the functioning of the brain.

17 Nov 2010

New slice-tilting instrument for in-vitro research on brain tissue

17 Nov 2010

China Medical second quarter revenue increases 21.5% to RMB201.8 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2010

17 Nov 2010

Pre-term births are leading cause of health problems in infants and cost the U.S. over $26 billion annually

The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births --- births at less than 37 weeks of gestation --- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.

17 Nov 2010

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study

Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.

17 Nov 2010

UMass, PolyMedix receive Phase 2 STTR contract to conduct test on antimicrobial compounds

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, Amherst (UMass), have received a Phase 2 Small Business Technology Transfer (STTR) contract in the amount of $750,000.

17 Nov 2010

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced that the company and the University of California, San Francisco (UCSF), have received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop an innovative system for characterizing the role transporter proteins play in the disposition of drugs by the liver.

16 Nov 2010

diaDexus third quarter revenue increases 26% to $3.2 million

diaDexus, Inc., a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced financial results for the third quarter of 2010.

15 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Lophius receives U.S. patent for UREA technology platform

Lophius Biosciences announced today that the USTPO has granted the U.S. Patent US 78293318 entitled "Use of urea-adjuvanted polypeptides for diagnosis, prophylaxis and therapy".

15 Nov 2010

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.

15 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

12 Nov 2010

GPR124 protein controls growth of blood vessels into brains

One protein single-handedly controls the growth of blood vessels into the developing brains of mice embryos, according to researchers at the Stanford University School of Medicine. Understanding how the protein, a cellular receptor, functions could help clinicians battle brain tumors and stroke by choking off or supplementing vital blood-vessel development, and may enhance the delivery of drugs across the blood-brain barrier.

12 Nov 2010

NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010

NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona. The presentation was entitled DAS181 (Fludase), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling.

12 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its real-time PCR-based Epidermal Growth Factor Receptor Assay (the "EGFR PCR Assay") for the use of lung cancer targeted drugs from the State Food and Drug Administration of China (the "SFDA").

10 Nov 2010